Haleema Qayyum Abbasi

Dr. Haleema Qayyum Abbasi


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AGAman Goyal
Aman Goyal
HAHaleema Qayyum Abbasi
Haleema Qayyum Abbasi
SYShreyas Yakkali
Shreyas Yakkali
AKAbdul Moiz Khan
Abdul Moiz Khan
MTMuhammad Daoud Tariq
Muhammad Daoud Tariq
RKRozi Khan
Rozi Khan
Background: Chemotherapy-related cardiac dysfunction (CTRCD) significantly affects patients undergoing anthracycline (AC) therapy, with a prevalence ranging from 2% to 20%. Reduced left ventricular ejection fraction (LVEF) and left ventricular global longitudinal strain (LV GLS) are prognostic parameters for CTRCD detection. Our study aimed to investigate the role of emerging parameters such as left atrial strain (LAS). Methods: We searched multiple databases for studies comparing LAS changes post-AC versus pre-AC therapy in patients with cancer. Primary outcomes included left atrial reservoir strain (LASr), left atrial conduit strain (LAScd), and left atrial contractile strain (LASct). RevMan (v5.4) was used to pool the standardized mean difference (SMD) under a random effects model, with p < 0.05 as the threshold for statistical significance. Results: In an analysis of 297 patients across five studies, AC therapy significantly lowered LASr (SMD = −0.34, 95% CI:−0.55, −0.14, I2 = 0%, p = 0.0009) and LAScd (SMD = −0.41, 95% CI: −0.59, −0.23, I2 = 0%, p < 0.00001) levels. Conversely, LASct demonstrated no significant change (SMD = 0.01, 95% CI: −0.21, 0.23, I2 = 9%, p = 0.95). AC therapy also significantly reduced LV GLS (SMD = −0.31, 95% CI: −0.51, −0.11, I2 = 0%, p = 0.003). While not statistically significant, LVEF decreased (SMD = −0.20, 95% CI: −0.42, 0.03, I2 = 0%, p = 0.09), and left atrial volume index trended higher (SMD = 0.07, 95% CI: −0.14, 0.27, I2 = 0%, p = 0.52) after AC therapy. Conclusions: AC treatment led to reduced LAS and LV GLS values, indicating its potential as an early CTRCD indicator. Larger trials are required to fully explore their clinical significance.

4 October 2024 in Medicine
Verified
Journal Article
Open access
HJHritvik Jain
Hritvik Jain
DDDebankur Dey
Debankur Dey
RORamez M. Odat
Ramez M. Odat
AHAyham Mohammad Hussein
Ayham Mohammad Hussein
HAHaleema Qayyum Abbasi
Haleema Qayyum Abbasi
RYRukesh Mbbs Yadav
Rukesh Mbbs Yadav
Background: Gastric outlet obstruction (GOO) refers to mechanical obstruction at the level of the gastric outlet and is associated with significantly impacted quality of life and mortality. Duodenal stenting (DS) offers a minimally invasive approach to managing GOO but is associated with a high risk of stent obstruction. Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) is a novel intervention that uses lumen-apposing metal stents to open the restricted lumen. The current evidence comparing EUS-GE to DS is limited and inconsistent. Methods: We conducted a systematic literature search on PubMed, Embase, Cochrane, Scopus, and clinicaltrials.gov to retrieve studies comparing EUS-GE to DS for GOO. Odds ratios (OR) and mean differences (MD) with their 95% confidence intervals (CI) were pooled using the DerSimonian-Laird inverse variance random-effects model. Statistical significance was set at P < .05. Results: Ten studies with a total of 1275 GOO patients (585: EUS-GE and 690: DS) were included. EUS-GE was associated with statistically significant higher clinical success [OR: 2.52; 95% CI: 1.64, 3.86; P < .001], lower re-intervention rate [OR: 0.12; 95% CI: 0.06, 0.22; P < .00001], longer procedural time [MD: 20.91; 95% CI: 15.48, 26.35; P < .00001], and lower risk of adverse events [OR: 0.49; 95% CI: 0.29, 0.82; P = .007] than DS. Technical success [OR: 0.62; 95% CI: 0.31, 1.25] and the length of hospital stay [MD: −2.12; 95% CI: −5.23, 0.98] were comparable between the 2 groups. Conclusion: EUS-GE is associated with higher clinical success, longer total procedural time, lower re-intervention rate, and lower risk of adverse events than DS. Technical success and the length of hospital stay were comparable between the 2 groups. EUS-GE appears to be a safe and effective procedure for managing GOO. Further large, multicentric randomized controlled trials are warranted to investigate the safety and outcomes of EUS-GE in patients with malignant GOO.

6 June 2023 in International Journal of Surgery
Verified
Journal Article
Open access
HAHaleema Qayyum Abbasi
Haleema Qayyum Abbasi
MAMaryyum Mbbs Adeena
Maryyum Mbbs Adeena
AKAbdul Moiz Khan
Abdul Moiz Khan
SSSyeda Shahnoor
Syeda Shahnoor
MOMalik Olatunde Oduoye
Malik Olatunde Oduoye
WNWechuli Polyne Nafula
Wechuli Polyne Nafula
An abstract is unavailable. This article is available as a PDF only.

25 September 2024 in International Journal of Cardiology Cardiovascular Risk and Prevention
Verified
Journal Article
Open access
AGAman Goyal
Aman Goyal
HAHaleema Qayyum Abbasi
Haleema Qayyum Abbasi
YMYusra Mashkoor
Yusra Mashkoor
AKAbdul Moiz Khan
Abdul Moiz Khan
SSSamia Aziz Sulaiman
Samia Aziz Sulaiman
BBBansal Bansal
Bansal Bansal
Although many chronic inflammatory conditions are linked to elevated cardiovascular risk, the specific extent of this risk in ANCA-associated vasculitis (AAV) remains elusive, largely due to the disease's rarity. Our study sought to clarify the cardiovascular risks and mortality linked to AAV. A systematic literature review was conducted across multiple databases from their inception until April 2024 to identify studies comparing cardiovascular outcomes in patients with and without AAV. R Studio's meta package was used to pool risk ratios under the random-effects model, and statistical significance was set at p < 0.05. Nine observational studies involving 45024 individuals were included in this analysis. Patients with AAV exhibited a significantly elevated risk of stroke (RR = 1.43, 95 % CI: 1.12–1.83, I2 = 62 %, p = 0.0048), myocardial infarction (RR = 1.49, 95 % CI: 1.25–1.79, I2 = 0 %, p < 0.0001), ischemic heart disease (RR = 1.40, 95 % CI: 1.24–1.58, I2 = 1 %, p < 0.0001), venous thromboembolism (RR = 2.57, 95 % CI: 1.70–3.90, I2 = 74 %, p < 0.0001), and pulmonary embolism (RR = 3.53, 95 % CI: 2.82–4.42, I2 = 9 %, p < 0.0001), deep vein thrombosis (RR: 4.21; 95 % CI: 2.00–8.86; p = 0.0002), heart failure (RR = 1.63, 95 % CI: 1.39–1.90, I2 = 0 %, p < 0.0001), and cardiovascular disease-related mortality (RR = 1.79, 95 % CI: 1.07–3.00, I2 = 0 %, p = 0.0256) compared to patients without AAV. This meta-analysis underscores a notable increase in adverse cardiovascular events among patients with AAV, underscoring the need for comprehensive cardiovascular care and diligent monitoring in this patient cohort.


25 October 2023 in Health Science Reports
Verified
Journal Article
Open access
HAHaleema Qayyum Abbasi
Haleema Qayyum Abbasi
MOMalik Olatunde Oduoye
Malik Olatunde Oduoye
Introduction: Respiratory syncytial virus (RSV), an RNA virus of the family Paramyxoviridae, is the most common cause of respiratory tract diseases, including upper and lower respiratory tract infections in adults. Researchers worldwide have been working for decades to develop an RSV vaccine that is both safe and cost‐effective.Aim: This correspondence aims to highlight the recent breakthroughs in the immunization against RSV for older adults (60 years and above), encompassing the newly sanctioned prophylactic agent by the FDA, drawing attention to its side effects that need to be taken care of and providing clear recommendations to maximize the potential influence of these advancements on RSV‐related diseases globally.Methodology: We did a literature search on RSV among older adults and its treatment on PubMed, Google Scholar, ResearchGate and FDA databases within 10 years. Keywords used for our search were; “Respiratory Syncytial Virus,” “Older adults,” “FDA,” “Arexvy,” and “Immunization.”Result: We found approximately 6000–10,000 lives and 60,000–160,000 hospital admissions among adults aged 65 years and older each year in the world, especially in the United States of America. Currently, there is no vaccine or targeted treatment for RSV for the most affected individuals, that is, the older adults, who are given supportive care. Recently, the USA‐ Food and Drug Administration (FDA) approved Arexvy (a recombinant subunit RSV vaccine) based on its encouraging results demonstrating acceptable safety and efficacy in a large‐scale multi‐centered Phase 3 trial.Conclusion: Authorization of Arexvy, although a breakthrough in the field of research, needs to be approached with a blend of optimism tempered by caution. Robust studies, including large‐scale randomized controlled trials, prospective cohort studies and systematic reviews and meta‐analyses, need to be conducted to ascertain its safety and efficacy.